Publication | Open Access

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

Advanced NsclcPrognostic BiomarkersTumor Pd-l1OncologyMedicineBiomarker TargetImmune Checkpoint InhibitorClinical OutcomesPharmacotherapyCancer TreatmentPharmacologyRadiation OncologyLung CancerHealth Sciences